Meeting
2015 ASCO Annual Meeting
Phase I trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A Children’s Oncology Group Study.
Authors
Robin Elizabeth Norris
Rainbow Babies and Children's Hosp, Moreland Hills, OH
Robin Elizabeth Norris , Elizabeth Fox , Joel M. Reid , Andrew T. Ralya , Xiaowei Liu , Charlotte H. Ahern , Charles Minard , Jodell Dahl , Rachel Eubank , Brenda Weigel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT01748721
Citation
J Clin Oncol 33, 2015 (suppl; abstr 10036)
DOI
10.1200/jco.2015.33.15_suppl.10036
Abstract #
10036
Poster Bd #
106
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A phase 1 study of the c-Met inhibitor tivantinib (ARQ 197, IND#112603) in children with relapsed or refractory solid tumors: A Children’s Oncology Group study.
First Author: James I. Geller
Poster
2013 ASCO Annual Meeting
A phase I trial and pharmacokinetic study of trebananib (AMG386) in children with recurrent or refractory solid tumors: A Children’s Oncology Group Phase 1 Consortium report.
First Author: Sarah Leary
Poster
2012 ASCO Annual Meeting
A first-in-human phase I study of MORAb-004 (M4), a humanized monoclonal antibody recognizing endosialin (TEM-1), in patients with solid tumors.
First Author: Luis A. Diaz Jr.
Poster
2011 ASCO Annual Meeting
A pediatric phase I trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A Children's Oncology Group Phase I Consortium Study.
First Author: T. R. Hummel